Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to WashU Medicine.

close  


Visit the News Hub

Breath carries clues to gut microbiome health

Findings in children, mice could pave way to new diagnostic tools, faster treatment

by Marta WegorzewskaJanuary 22, 2026

graphic of a child exhaling chemicalsSara Moser/WashU Medicine

The human gut is home to trillions of beneficial microbes that play a crucial role in health. Disruptions in this delicate community of bacteria and viruses — called the gut microbiome — have been linked to obesity, asthma and cancer, among other illnesses. Yet quick diagnostic tools to identify issues within the microbiome that could be addressed to treat these conditions are lacking.

Now, researchers at Washington University School of Medicine in St. Louis and Children’s Hospital of Philadelphia have shown that disease-associated bacteria in the gut can be detected through exhaled breath. They found that chemicals released by gut microbes and captured from the breath of children and mice can reveal the composition of the bacteria living in the intestines. They also showed that breath samples from children with asthma could predict the presence of the bacterium linked to the condition.

The findings appear Jan. 22 in Cell Metabolism and could pave the way for a rapid, non-invasive test to monitor and diagnose gut health issues simply by breathing into a device.

“Rapid assessment of the gut microbiome’s health could significantly enhance clinical care, especially for young children,” said Andrew L. Kau, MD, PhD, an associate professor in the John T. Milliken Department of Medicine at WashU Medicine and senior author on the study. “Early detection could lead to prompt interventions for conditions like allergies and serious bacterial infections in preterm infants. This study lays the groundwork for developing such crucial diagnostic tools.”

graphic of microbes in the gut and the chemicals they produce that we exhaleSara Moser/WashU Medicine
Researchers at WashU Medicine and Children’s Hospital of Philadelphia found that chemicals released by gut microbes and captured from the breath of children and mice can be used as a proxy for the bacteria living in the intestines.

In the process of digesting food that the body cannot, microbes release compounds, known as volatile organic compounds, that are excreted from the body through exhaled breath. The researchers, including Kau; first author Ariel J. Hernandez-Leyva, a WashU Medicine MD/PhD student; and co-corresponding author Audrey R. Odom John, MD, PhD, the Stanley Plotkin Endowed Chair in Pediatric Infectious Diseases at Children’s Hospital of Philadelphia, wondered if the types of compounds in breath can help identify the bacterial composition of the gut microbiome.

Hernandez-Leyva and his colleagues conducted a clinical study at WashU Medicine of children ages six to 12. They analyzed the breath and stool of 27 healthy children for microbe-derived compounds and gut microbes, respectively, to figure out which microbes were linked with which breath compounds.

The team found that the compounds in the children’s breath matched the compounds known to be produced by the very microbes present in their stool, confirming that breath is a good proxy for the microbial community in the gut. They obtained similar results in mice by transplanting bacteria into animals without gut microbes of their own and finding again that gut bacteria can be identified from breath compounds.

The researchers also compared breath and stool samples from healthy children to samples from children with asthma. Pediatric asthma — which affects nearly 5 million kids in the U.S. — is associated with an increased intestinal abundance of the bacterium Eubacterium siraeum. Through breath analysis, they were able to predict the abundance of E. siraeum in kids with asthma.

Such information on E. siraeum abundance would be valuable for spotting early signs of microbiome changes that might exacerbate asthma symptoms. Similarly, routine screening of microbiome health through breath tests in infants born prematurely, for instance, might spot disruptions to the developing microbiome that portend infection.

The results of the new study may help inform the development of a non-invasive microbiome breath test. Breath tests for detecting microbes have previously been developed by WashU Medicine researchers, including one that can detect the COVID-19 virus in less than a minute.

“One of the key barriers to integrating our knowledge of the microbiome into clinical care is the time it takes to analyze the data on the microbiome,” said Hernandez-Leyva. “Breath analysis offers a promising, non-invasive way to probe the gut microbiome and can transform how we diagnose disease in medicine.”

Hernandez-Leyva AJ, Berna AZ, Bui MH, Liu Y, Rosen AL, Lint MA, Whiteside SA, Jaeger N, McDonough RT, Joardar N, Santiago-Borges J, Tomera CP, Luo W, Odom John AR, Kau AL. The gut microbiota shapes the human and murine breath volatilome. Cell Metabolism. January 22, 2026. DOI: 10.1016/j.cmet.2025.12.013.

This work was supported by the National Institutes of Allergy and Infectious Diseases, grant number R21 AI154370; National Institute of General Medical Sciences, grant number T32 GM007200; National Institute of Diabetes and Digestive and Kidney Diseases, grant number F30 DK127584; National Institute of Child Health and Human Development, grant number R01 HD109963 of the National Institutes of Health (NIH); and the St. Louis Children’s Hospital Children’s Discovery Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Competing Interests: Audrey R. Odom John is on the scientific advisory board of Pluton Biosciences and receives funding from the NIH, Department of Defense, USDA, Doris Duke Charitable Foundation, and the Bill and Melinda Gates Foundation. Andrew L. Kau is a scientific advisor for Ancilia Biosciences and Inimmune and receives licensing fees from Ancilia Biosciences; and receives funding from the NIH and Doris Duke Charitable Foundation.

About WashU Medicine

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with more than 3,000 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 83% since 2016. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,000 faculty physicians practicing at 130 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children’s hospitals — the academic hospitals of BJC HealthCare — and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri. WashU Medicine physicians also treat patients at BJC’s community hospitals in our region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

Marta covers pathology & immunology, pediatrics, obstetrics & gynecology, anesthesiology, ophthalmology and technology management, among other topics. She holds a bachelor’s degree in biology from Georgetown University and a PhD in immunology from the University of California, San Francisco. She did her postdoctoral work in Washington University’s Department of Pathology & Immunology. Marta joined WashU Medicine Marketing & Communications in 2023 after working as a science writer in the Department of Biology on the Danforth Campus for five years.